ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÎÒÃǵķþÎñ

×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕߣ¬NG28ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²âΪȫÇò¿Í»§Ìṩһվʽ¼ìÑé¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°¼¼Êõ·þÎñ¡£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÐÐÒµ½â¾ö·½°¸

·þÎñÄÜÁ¦ÒÑÈ«ÃæÁýÕÖµ½·ÄÖ¯·þ×°¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉú»î¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§½¡¿µ¡¢Ê³Æ·¼°Å©²úÎï……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÌØÉ«·þÎñ

È«Ãæ±£ÕÏÆ·ÖÊÓëÄþ¾²£¬Íƶ¯ºÏ¹æÓ봴У¬ÕÃÏÔÆ·ÅƾºÕùÁ¦£¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü½¡¿µ¡¢¸üÄþ¾²¡¢¸üÂÌÉ«µÄ¿ÉÁ¬ÐøÉú³¤¡£

¼ÓÈëÎÒÃÇ
È˲ÅÕþ²ß
ÕÐÏÍÄÉÊ¿
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
È˲ÅÕþ²ß
±£ÕÏÔ±¹¤»ù±¾È¨ÒæÓ븣Àû£»Ìṩרҵ¼¼ÄÜÅàѵ£¬´Ù½øÔ±¹¤Éú³¤£»¿ªÕ¹¸»ºñ¶à²ÊµÄ»î¶¯£¬Æ½ºâÔ±¹¤ÊÂÇéÓëÉú»î¡£
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÕÐÏÍÄÉÊ¿
»¶Ó­¼ÓÈëÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²â¸÷ÈËÍ¥£¬ÎÒÃǽ«ÎªÄã´î½¨Ò»¸ö³äʵʩչ²ÅÆø£¬ÊµÏÖÖ°ÒµÀíÏëµÄÎę̀¡£
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÐÂÎÅ×ÊѶ

¡°ÊÀ½çÅÁ½ðÉ­²¡ÈÕ¡±¡ª¡ªÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿°¬ÆÕ¹Ø°®ÅÁ½ðÉ­²¡»¼Õߣ¬ÖúÄúÔ¶Àë¡°Õð²üÂé±Ô¡±

Ðû²¼Ê±¼ä£º2024-04-11 ä¯ÀÀ´ÎÊý£º546

“ÊÖ¶¶” = ÅÁ½ðÉ­£¿

      2024Äê4ÔÂ11ÈÕÊǵÚ27¸ö“ÊÀ½çÅÁ½ðÉ­²¡ÈÕ”¡£ÅÁ½ðÉ­ÊÇÒ»ÖÖ³£¼ûµÄÀÏÄêÉñ¾­ÏµÍ³ÍËÐÐÐÔ¼²²¡¡£¾­³£ÊÖ¶¶¾ÍÊÇÅÁ½ðÉ­²¡£¿

      ÅÁ½ðÉ­²¡£¨Parkinson's Disease£©£¬ÓֳƓÕð²üÂé±Ô”£¬ÊÇÒ»ÖÖ³£¼ûµÄÀÏÄêÉñ¾­ÏµÍ³ÍËÐÐÐÔ¼²²¡£¬ÌåÏÖ³ö¾ßÓÐÌØÕ÷ÐÔµÄÔ˶¯Ö¢×´£¬°üÂÞÔ˶¯³Ù»º¡¢¾²Ö¹ÐÔÕð²ü¡¢¼¡ÈâǿֱµÈ£¬Í¬Ê±»á°éÓÐÐá¾õÕϰ­¡¢Ë¯ÃßÕϰ­µÈ·ÇÔ˶¯Ö¢×´¡£

      ÔÚÎÒ¹ú 65 Ëê¼°ÒÔÉÏÈËȺÖУ¬ÅÁ½ðÉ­²¡·¢²¡ÂÊԼΪ1.7%£¬Ô¤¼Æµ½ 2030 Ä꣬ÎÒ¹úÅÁ½ðÉ­²¡»¼²¡ÈËÊý½«µ½´ï 500 ÍòÈË ¡£Ëæ×ÅÈË¿ÚÀÏÁ仯µÄ¼Ó¾ç£¬Öйú¼´½«³ÉΪÅÁ½ðÉ­²¡È˿ڵÄÊÀ½çµÚÒ»´ó¹ú¡£

 

ÅÁ½ðÉ­Ñо¿ÏÖ×´

      ½üÄêÀ´ÔÚ·ÖÎöÅÁ½ðÉ­²¡£¨PD£©·¢²¡»úÖÆ·½Ã棬Ñо¿È¡µÃÁËÒ»¶¨µÄ½øÕ¹¡£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

ͼƬÀ´Ô´£ºMov Disord. 2013 Jan;28(1):24-30.

 

      Ò»¸ö¶àÊÀ¼ÍÒÔÀ´£¬Î§ÈÆPDÊÇÓÉÓÚ»·¾³ÒòËØ¡¢ÒÅ´«ÒòËØ»òÊÇÁ½ÕßÏà½áºÏ¶øÖ²¡µÄÕùÂÛµÄÑо¿Ò»Ö±´æÔÚ²»ÉÙÕùÂÛ¡£

 

01 ÒÅ´«ÒòËØÓëPD

      ³£È¾É«ÌåÒþÐÔÒÅ´«ÓëParkin»ùÒò±»´óÁ¿µÄ·¢ÏÖÓÚÔç·¢ÐÔ²¡Àí³ÂËßÖУ¬´óÁ¿µÄÖ¤¾ÝÏÔʾÁ˼Ò×åÐÍÅÁ½ðÉ­²¡µÄÖ÷Òª»ùÒò°üÂÞ SNCA¡¢ PARK2»ùÒò¡¢PTENÓÕµ¼¼¤Ã¸ 1(PINK1)¡¢DJ-1ºÍ¸»º¬ÁÁ°±ËáÖØ¸´¼¤Ã¸2(LRRK2)µÈ»ùÒò¡£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

ͼƬÀ´Ô´£ºLancet 2015; 386: 896–912

 

02 Éú»îϰ¹ß

      һЩÉú»îϰ¹ß¿ÉÓ°ÏìPDµÄ·¢²¡£¬ÎüÑÌÓëPDÖ®¼äµÄ¹ØÏµÊǽü¼¸ÄêÑо¿µÄÈȵ㡣һЩÁ÷Ðв¡Ñ§Ñо¿ÏÔʾÎüÑÌÓëÅÁ½ðÉ­²¡µÄ·¢Éú³Ê¸ºÏà¹Ø£¬Ñ̲ÝÖеÄÄá¹Å¶¡ºÍ¶Ô±½¶þ·Ó£¬ÌرðÊÇÄá¹Å¶¡±»·¢ÏÖ¿ÉÒÔ½µµÍPD·¢ÉúÂÊ¡£Ñ̲ݵÄÉñ¾­±£»¤×÷Óøü¶àµÄ±»¹é¹¦ÓÚÄá¹Å¶¡£¬ÏÖÔÚ¶àÈÏΪÄá¹Å¶¡Ö÷Ҫͨ¹ýÑ̼îÐ͵¨¼îÄÜÊÜÌå(nAChRs);¾¶·¢»Ó×÷Óá£

 

ÒÅ´«»ùÒò

      SNCA»ùÒòÊǵÚÒ»¸öÓëPDÏà¹ØÇÒÂôÁ¦¼²²¡µÄÒ»ÖÖº±¼ûµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«µÄ»ùÒò¡£¾¡¹Ü 1997Äê·¢ÏÖÁËÕâ¸ö»ùÒò£¬µ«ÊÇSNCAµÄÂѰײúÎï½öһͻ´¥ÂѰ×È´ÉÐδ±»·ÖÎö£¬½ö¼ÙÉèÁËÍ»´¥µÄ¿ÉËÜÐÔ×÷Óá£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

ͼƬÀ´Ô´£ºNeurobiology of Aging Volume 36, Issue 3, March 2015, Pages 1505-1518

 

      SNCA»ùÒòµÄA53T¡¢ A30PºÍE46KµÄ´íÒâÍ»±äµ¼ÖÂÍ»´¥ÂѰ×ˮƽµÄÌá¸ß£¬Ô½·¢ÈÝÒ×ÐγÉÏËά£¬´Ó¶ø¼Ó¿ìÁË·Ò×СÌåµÄÐγÉ¡£ÓÐȤµÄÊÇһЩÒѱ»±¨µÀÉ¢·¢ÐÔPD»¼ÕßÔÚ½öһͻ´¥ÂѰ×ÖÐÒ²ÓлùÒòÍ»±ä£¬Ô¤Ê¾×ŸûùÒò¿ÉÄÜͬʱ¼ÓÈë¸Ã²¡ÒÅ´«ºÍÉ¢·¢ÐÎʽµÄ²¡ÀíÉúÀí»úÖÆ¡£Òò´Ë½øÐÐÒÅ´«»ùÒòµÄÏà¹Ø¼ì²â£¬ÓÐÖúÓÚµÚһʱ¼äÕÆÎÕPDµÄ·çÏÕ£¬¸üÓÐЧµÄ½øÐн¡¿µ¹ÜÀí¡£

 

ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿°¬ÆÕ--ÅÁ½ðÉ­²¡·çÏÕÆÀ¹À

      ͨ¹ý¶ÔÅÁ½ðÉ­²¡Ïà¹Ø»ùÒò½øÐмì²â£¬¿ÉÒÔÆÀ¹ÀÅÁ½ðÉ­²¡£¨PD£©µÄÒÅ´«·çÏÕ£¬Æ¾¾ÝÒÅ´«·çÏյįéá«£¬²Î¿¼Ïà¹Ø½¨Òé½øÐÐÔ¤·À¼à²â£¬¹Ø×¢²¢½øÐн¡¿µ¹ÜÀí¡£

 

²úÎïÓÅÊÆ

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

 

ÍÆ¼ö¼ì²âÈËȺ

  • ÓÐÅÁ½ðÉ­²¡£¨PD£©¼Ò×åÊ·µÄ¸ß·çÏÕÈËȺ
  • ÒÉËÆ»¼ÓÐÅÁ½ðÉ­²¡£¨PD£©¼°Ïà¹Ø¼²²¡µÄÈËȺ
  • ÓÐÇá¶ÈÉñ¾­ÏµÍ³ÍËÐÐÐÔÇé¿öÐèÒª½øÐÐΣÏÕ·Ö²ãµÄÈËȺ
  • ¹Ø×¢Éñ¾­ÈÏÖª¼²²¡ºÍÄÔ½¡¿µµÄÈËȺ

 

²Î¿¼ÎÄÏ×

[1] Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27: 617–26.

[2] Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013; 84: 409–15.

[3] Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord 2014; 29: 195–202.

ÍøÕ¾µØÍ¼